WAT

AI Research

BD spin-off completed → Waters receives $4B in cash; ARES-G3 rheometer launched with 80% faster testing

Waters Corporation completed the spin-off and combination with BD's Biosciences & Diagnostic Solutions business on February 9, 2026, receiving $4.0 billion in cash and creating a global life sciences leader with four divisions. The company launched the ARES-G3 Rheometer on March 9, capturing 25,000 data points/second and reducing standard test times by up to 80%. 2026 guidance projects 5.5-7% organic revenue growth with total revenue of $6.405-$6.455B and adjusted EPS of $14.30-$14.50.